Rheostat is working to develop novel treatments for neurodegenerative disease through modulation of mitophagy and autophagy. Its central thesis is that the degradation of toxic cellular components is a fundamental node of biology. The company is working to leverage its understanding of these pathways to discover and develop novel small molecules that will restore cellular balance and treat neurodegenerative and rare diseases.
Market
Neurodegenerative diseases
Location
Cambridge,
MA,
USA
Coinvestors
AbbVie Biotech Ventures, Alexandria Real Estate Equities, Amgen Business Development, Dementia Discovery Fund, Mayo Clinic, MRL Ventures Fund, SV Health Investors